No FDA-approved generic version of semaglutide exists. The brand-name products, Ozempic and Wegovy (injections) and Rybelsus (oral tablets), are all manufactured exclusively by Novo Nordisk and protected by patents that don’t expire in the U.S. until 2032. What you may have seen advertised as “generic semaglutide” is almost certainly a compounded version, which is a fundamentally different product with different regulatory oversight.
Why No Generic Exists Yet
Generic drugs can only enter the U.S. market after the original manufacturer’s patents expire. Novo Nordisk holds patents on semaglutide that extend through 2032 in the United States, though its patents in some other countries expire sooner. Until that date, no pharmaceutical company can legally produce and sell an FDA-approved generic copy.
This applies to all three brand-name forms: Ozempic (used for type 2 diabetes), Wegovy (approved for weight management), and Rybelsus (the oral tablet). None of them have a generic equivalent available, and none will for several more years.
Compounded Semaglutide Is Not a Generic
The products marketed at lower prices through telehealth companies, med spas, and compounding pharmacies are compounded semaglutide, not generics. The distinction matters. A true generic must prove to the FDA that it contains the same active ingredient, in the same dose and form, and works identically in the body. Compounded drugs skip that process entirely.
Compounding pharmacies mix medications to order, typically for individual patients with a prescription. Federal law allows this under two pathways. Under Section 503A, a pharmacy can compound a drug based on a valid prescription for a specific patient. Under Section 503B, larger “outsourcing facilities” can produce compounded drugs in batches but face additional FDA oversight. Both pathways normally prohibit making copies of commercially available drugs, with one major exception: when the FDA-approved version is on the official drug shortage list.
Semaglutide injections were on that shortage list for an extended period due to overwhelming demand. During that window, compounding pharmacies could legally produce semaglutide. As the shortage stabilizes, the FDA has signaled that this flexibility is tightening. Outsourcing facilities that received orders while the drug was in shortage get a 60-day grace period after it’s removed from the shortage list, but they cannot continue filling new orders indefinitely.
Safety Concerns With Compounded Versions
The FDA has raised specific concerns about what’s actually in some compounded semaglutide products. The agency found that certain compounders use salt forms of the molecule, such as semaglutide sodium and semaglutide acetate, rather than the base form used in Ozempic and Wegovy. These are chemically different active ingredients, and the FDA says it has no information on whether they behave the same way in the body.
That’s a significant gap. With an FDA-approved drug, years of clinical trials establish exactly how the active ingredient is absorbed, how long it lasts, and what side effects it causes at specific doses. Compounded versions using alternative salt forms haven’t gone through that testing. You could be getting a product that’s stronger, weaker, or absorbed differently than expected. The FDA has stated it is “not aware of any lawful basis” for using these salt forms in compounding.
Beyond the active ingredient itself, compounded drugs don’t undergo the same manufacturing quality checks as approved pharmaceuticals. Contamination, inconsistent dosing, and sterility problems are all risks that FDA approval is designed to prevent.
Novo Nordisk’s Legal Push Against Compounders
Novo Nordisk has been actively pursuing legal action against compounding pharmacies producing semaglutide. The company frames these products as “illicit compounding” and has an enforcement program targeting what it describes as a spectrum of unlawful activities: product imitations, unlicensed entities selling active ingredients directly to patients, and compounded products that violate existing patents.
The company has also pushed back against compounders who make small modifications to their formulations, calling these “manipulated, unnecessary and pretextual changes to ingredients, routes of administration or dosages.” As the drug shortage resolves and the legal basis for compounding narrows, this enforcement pressure is likely to intensify.
What This Means for Cost
Price is the main reason people search for a generic. The list price for a one-month supply of Ozempic in the U.S. is roughly $936, and Wegovy runs about $1,349 per month at the maintenance dose. Insurance coverage varies widely, and many people with weight-loss prescriptions find their plans won’t cover the cost.
Compounded semaglutide has typically been available for a fraction of those prices, which explains its popularity. But as the regulatory landscape shifts and compounding access potentially narrows, that pricing advantage may not last. Novo Nordisk and other manufacturers have introduced savings programs for certain eligible patients, though these often apply only to specific diagnoses or insurance situations.
The earliest a true FDA-approved generic could reach the market is 2032, when the core U.S. patents expire. Even then, the timeline depends on how quickly generic manufacturers file applications and whether Novo Nordisk pursues additional patent protections. For context, it’s common for brand-name drugmakers to file secondary patents or pursue legal strategies that delay generic entry beyond the original expiration date.
How to Tell What You’re Getting
If a provider or pharmacy offers you “semaglutide” at a steep discount, it’s compounded. There is no other explanation at this point. That doesn’t automatically mean it’s dangerous, but it does mean the product hasn’t been through FDA review, the active ingredient may differ from what’s in the approved versions, and your legal protections as a consumer are more limited.
You can verify whether a pharmacy is a registered 503B outsourcing facility through the FDA’s public database. Outsourcing facilities face more regulatory scrutiny than standard compounding pharmacies, including periodic FDA inspections. If you’re considering a compounded product, knowing which category your pharmacy falls into gives you at least some measure of how much oversight applies.